Scientific research on nattokinase shows it is a potent fibrinolytic enzyme derived from fermented soy. Controlled studies report reductions in blood pressure and modulation of coagulation factors in humans. At higher intake levels around 10,800 FU daily, extended use has been associated with reduced carotid plaque thickness and improved lipid profiles in large clinical cohorts, with a favorable safety profile. Lower doses show smaller or inconsistent effects on lipids. Mechanistic data suggest effects on endothelial function and vascular inflammation. Traditional intake from natto in Japan typically provides ~1,000–2,000 FU per serving, alongside vitamin K2 (MK-7), soy isoflavones, probiotics, and fermentation-derived peptides. Supplemental nattokinase isolates the enzyme, usually 2,000 FU daily for general support, with higher doses used in interventional settings under supervision. This raises an important question: are observed cardiovascular benefits in natto-consuming populations attributable to nattokinase alone, or to the broader fermented soy matrix including K2 and isoflavones? Conversely, does isolated supplementation replicate the vascular effects without the additional bioactive compounds? Another layer worth discussing is soy’s isoflavone content. While fermented soy contains phytoestrogens with generally weak and context-dependent activity, concerns about estrogenic signaling persist. Does fermentation meaningfully alter isoflavone bioactivity? And does isolated nattokinase avoid that concern entirely, or remove potentially synergistic compounds? The distinction between whole-food exposure and enzymatic isolation deserves more rigorous comparative trials.